Crispr: A Fallen Angel In Gene Editing
October 16, 2021 at 00:31 AM EDT
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it becomes profitable, investors will come flocking back.